{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:20:40Z","timestamp":1769242840593,"version":"3.49.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,3,3]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>High-risk SMM patients\u2019 immune status is mildly impaired as compared with age-matched healthy individuals. High-risk SMM patients can be effectively immunomodulated by lenalidomide, even when combined with low-dose dexamethasone.<\/jats:p>","DOI":"10.1182\/blood-2015-10-662320","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T23:44:29Z","timestamp":1450136669000},"page":"1151-1162","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis"],"prefix":"10.1182","volume":"127","author":[{"given":"Bruno","family":"Paiva","sequence":"first","affiliation":[{"name":"Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain;"}]},{"given":"Mar\u00eda Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Instituto de Investigaion Biomedica de Salamanca, Instituto de Biolog\u00eda Molecular y Celular del Cancer (Universidad de Salamanca Centro de Investigaci\u00f3n del C\u00e1ncer), Salamanca, Spain;"}]},{"given":"Luis Ignacio","family":"Sanchez-Abarca","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Instituto de Investigaion Biomedica de Salamanca, Instituto de Biolog\u00eda Molecular y Celular del Cancer (Universidad de Salamanca Centro de Investigaci\u00f3n del C\u00e1ncer), Salamanca, Spain;"}]},{"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Instituto de Investigaion Biomedica de Salamanca, Instituto de Biolog\u00eda Molecular y Celular del Cancer (Universidad de Salamanca Centro de Investigaci\u00f3n del C\u00e1ncer), Salamanca, Spain;"}]},{"given":"Mar\u00eda-Bel\u00e9n","family":"Vidriales","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Instituto de Investigaion Biomedica de Salamanca, Instituto de Biolog\u00eda Molecular y Celular del Cancer (Universidad de Salamanca Centro de Investigaci\u00f3n del C\u00e1ncer), Salamanca, Spain;"}]},{"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Instituto de Investigaion Biomedica de Salamanca, Instituto de Biolog\u00eda Molecular y Celular del Cancer (Universidad de Salamanca Centro de Investigaci\u00f3n del C\u00e1ncer), Salamanca, Spain;"}]},{"given":"Luis A.","family":"Corchete","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Instituto de Investigaion Biomedica de Salamanca, Instituto de Biolog\u00eda Molecular y Celular del Cancer (Universidad de Salamanca Centro de Investigaci\u00f3n del C\u00e1ncer), Salamanca, Spain;"}]},{"given":"Miguel T.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Canarias, Tenerife, Spain;"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[{"name":"Hospital Sont Llatzer, Palma de Mallorca, Spain;"}]},{"given":"Felipe","family":"de Arriba","sequence":"additional","affiliation":[{"name":"Hospital Morales Messeguer, Murcia, Spain;"}]},{"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Fe, Valencia, Spain;"}]},{"given":"Ana-Isabel","family":"Teruel","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Valencia, Valencia, Spain;"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Hospital Miguel Servet, Health Research Institute Arag\u00f3n, Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Raras, Zaragoza, Spain;"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain;"}]},{"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain;"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol, Badalona, Spain;"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hospital General de Segovia, Segovia, Spain;"}]},{"given":"Gra\u00e7a","family":"Esteves","sequence":"additional","affiliation":[{"name":"Hospital de Santa Mar\u00eda, Lisboa, Portugal;"}]},{"given":"Juan Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Madrid, Spain; and"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain;"}]},{"given":"Jose Antonio","family":"Perez-Simon","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Rocio, Sevilla, Spain"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain;"}]}],"member":"234","reference":[{"issue":"9","key":"2019111721382506200_B1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3324\/haematol.2011.060780","article-title":"Genomic analysis of high-risk smoldering multiple myeloma.","volume":"97","author":"L\u00f3pez-Corral","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2019111721382506200_B2","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111721382506200_B3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2019111721382506200_B4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/leu.2012.128","article-title":"SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status.","volume":"26","author":"L\u00f3pez-Corral","year":"2012","journal-title":"Leukemia"},{"issue":"34","key":"2019111721382506200_B5","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111721382506200_B6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2019111721382506200_B7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/leu.2014.59","article-title":"Serial exome analysis of disease progression in premalignant gammopathies.","volume":"28","author":"Zhao","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2019111721382506200_B8","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/leu.2012.42","article-title":"Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.","volume":"26","author":"Paiva","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2019111721382506200_B9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma.","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111721382506200_B10","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/bcj.2015.32","article-title":"The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies.","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J"},{"issue":"7","key":"2019111721382506200_B11","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111721382506200_B12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"2019111721382506200_B13","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V98.9.2817","article-title":"Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment.","volume":"98","author":"Sze","year":"2001","journal-title":"Blood"},{"issue":"3-4","key":"2019111721382506200_B14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10428199809059231","article-title":"The expression of T cell related costimulatory molecules in multiple myeloma.","volume":"31","author":"Brown","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2019111721382506200_B15","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111721382506200_B16","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2019111721382506200_B17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"issue":"25","key":"2019111721382506200_B18","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111721382506200_B19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111721382506200_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3465.3465","article-title":"Long term follow-up on the tretament [sic] of high risk smoldering myeloma with lenalidomide plus low dose dex (rd) (phase III spanish trial): persistent benefit in overall survival [abstract].","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111721382506200_B21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4161\/onci.18963","article-title":"Are the immuno-stimulatory properties of lenalidomide extinguished by co-administration of Dexamethasone?","volume":"1","author":"Hsu","year":"2012","journal-title":"OncoImmunology"},{"issue":"5","key":"2019111721382506200_B22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111721382506200_B23","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2011-08-372680","article-title":"Effect of combined dexamethasone\/lenalidomide therapy on NK cell-receptor levels in myeloma patients.","volume":"118","author":"Carter","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111721382506200_B24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/cei.12343","article-title":"Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.","volume":"177","author":"Busch","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"2019111721382506200_B25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.","volume":"10","author":"Gandhi","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"issue":"10","key":"2019111721382506200_B26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrclinonc.2013.160","article-title":"Haematological cancer: Treatment of smoldering multiple myeloma.","volume":"10","author":"Rajkumar","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2019111721382506200_B27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"22","key":"2019111721382506200_B28","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111721382506200_B29","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111721382506200_B30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111721382506200_B31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/imm.12082","article-title":"Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy.","volume":"139","author":"Costello","year":"2013","journal-title":"Immunology"},{"issue":"7","key":"2019111721382506200_B32","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111721382506200_B33","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"11","key":"2019111721382506200_B34","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"4","key":"2019111721382506200_B35","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma.","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2019111721382506200_B36","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111721382506200_B37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2007-0127","article-title":"Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired.","volume":"13","author":"Mart\u00edn-Ayuso","year":"2008","journal-title":"Oncologist"},{"issue":"18","key":"2019111721382506200_B38","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111721382506200_B39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.leukres.2004.06.003","article-title":"High Th1\/Th2 ratio in patients with multiple myeloma.","volume":"29","author":"Ogawara","year":"2005","journal-title":"Leuk Res"},{"issue":"6","key":"2019111721382506200_B40","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/cncr.21746","article-title":"Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic\/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.","volume":"106","author":"P\u00e9rez-Andres","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2019111721382506200_B41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"issue":"26","key":"2019111721382506200_B42","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"2019111721382506200_B43","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance.","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"issue":"2","key":"2019111721382506200_B44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111721382506200_B45","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.2011.575","article-title":"The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma.","volume":"106","author":"Giannopoulos","year":"2012","journal-title":"Br J Cancer"},{"issue":"10","key":"2019111721382506200_B46","doi-asserted-by":"crossref","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS One"},{"issue":"6168","key":"2019111721382506200_B47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"6168","key":"2019111721382506200_B48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"1","key":"2019111721382506200_B49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds.","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111721382506200_B50","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"issue":"26","key":"2019111721382506200_B51","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111721382506200_B52","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2011.652106","article-title":"Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.","volume":"53","author":"Muthu Raja","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111721382506200_B53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2015.05.002","article-title":"Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.","volume":"297","author":"Scott","year":"2015","journal-title":"Cell Immunol"},{"issue":"7","key":"2019111721382506200_B54","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.4049\/jimmunol.0902070","article-title":"TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.","volume":"184","author":"Nagar","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"2019111721382506200_B55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ccell.2015.08.009","article-title":"Engineering anti-myeloma responses using affinity-enhanced TCR-engineered T cells.","volume":"28","author":"San Miguel","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/9\/1151\/1396031\/1151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/9\/1151\/1396031\/1151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T21:38:47Z","timestamp":1574026727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/9\/1151\/126473\/Immune-status-of-highrisk-smoldering-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,3,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-10-662320","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}